CF Drug's hidden impact on gut and lung bugs revealed
NCT ID NCT05937815
First seen Jun 22, 2026 · Last updated Jun 23, 2026 · Updated 1 time
Summary
This study tracks 253 cystic fibrosis patients starting a new drug combination (elexacaftor/tezacaftor/ivacaftor). Researchers collect sputum, stool, and blood samples at the start, 6 months, and 1 year to see how the drug changes bacteria and inflammation in the lungs and gut. The goal is to understand the drug's full effects beyond just breathing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AP-HM CRCM pédiatrique
RECRUITINGMarseille, France
Contact
-
AP-HP CRCM Robert debré
RECRUITINGParis, France
Contact
-
AP-PH Hopital Cochin service de pédiatrie
RECRUITINGParis, France
Contact
-
APHP Hopital Necker
RECRUITINGParis, France
Contact
-
CHRU de Lille CRCM Pédiatrique
RECRUITINGLille, France
Contact
-
CHU de Bordeaux - CRCM pédiatrique
RECRUITINGBordeaux, France
Contact
-
CHU de Grenoble Alpes CRCM pédiatrique
RECRUITINGGrenoble, France
Contact
-
CHU de Limoges CRCM Limousin
RECRUITINGLimoges, France
Contact
-
CHU de Montpellier
RECRUITINGMontpellier, France
Contact
-
CHU de Nancy
RECRUITINGNancy, France
Contact
-
CHU de Nice
RECRUITINGNice, France
Contact
-
CHU de Rouen
RECRUITINGRouen, France
Contact
-
CHU de Toulouse
RECRUITINGToulouse, France
Contact
-
Fondation Ildys, Roscoff Centre Hélio Marin - Clinique "Mucoviscidose"
RECRUITINGRoscoff, France
Contact
-
Hospices Civils de Lyon Service de pédiatrie, allergologie et mucoviscidose
RECRUITINGLyon, France
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Elexacaftor/Tezacaftor/Ivacaftor
What this could lead to
If successful, this could reveal how the drug improves gut and lung health in cystic fibrosis, guiding better future treatments.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove the drug works or is safe, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.